Title : The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.

Pub. Date : 2017 Jun

PMID : 28471247






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Areas covered: This review focuses on the main hematologic and non-hematologic toxicities correlated with the use of licensed antiangiogenic agents and PARP inhibitors in recurrent platinum-sensitive EOC, providing recommendations for their management. Platinum poly(ADP-ribose) polymerase 1 Homo sapiens